Hematology Oncology Expert Witness | Malpractice

Specialties & Experience of this Expert Witness

Additional Information

Dr. Ariel F. Grajales-Cruz, MD is a triple board-certified physician in Internal Medicine, Hematology, and Medical Oncology, internationally recognized for his expertise in multiple myeloma, hematologic malignancies, CAR-T cell therapies, and bispecific antibody treatments. With a strong record in clinical practice, research, and consulting, he is widely sought as a medical expert witness, advisor, and opinion leader. Dr. Grajales-Cruz is an Assistant Member in Malignant Hematology & Cellular Therapy at Moffitt Cancer Center in Tampa, Florida, a leading cancer research institution. His practice focuses on plasma cell disorders, leukemia, lymphoma, and complex blood cancers, with special emphasis on novel immunotherapies. He plays an active role in clinical trial development and real-world evidence studies, bridging patient care and pharmaceutical innovation. In 2022, he founded Grajales Medical Solutions Corp, a consulting practice providing expert medical opinions, litigation support, and advisory services to law firms, pharmaceutical companies, and biotech organizations. Through this platform, he delivers expert witness testimony, advisory board participation, and strategic guidance in drug safety, oncology malpractice, clinical trial evaluation, and healthcare policy. Dr. Grajales-Cruz earned his MD from Universidad Central del Caribe in Puerto Rico, completed residency in Internal Medicine at the VA Caribbean Healthcare System where he served as Chief Resident, and trained in Hematology & Oncology at Moffitt Cancer Center / University of South Florida. As an educator and mentor, he serves as faculty with the University of South Florida Morsani College of Medicine, teaching medical students, residents, and fellows. He has presented research and lectures at leading global conferences and is an active member of professional societies, including the American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), European Hematology Association (EHA), International Myeloma Society (IMS), European Society for Blood and Marrow Transplantation (EBMT), American Society for Transplantation and Cellular Therapy (ASTCT), and the Asociación Colombiana de Hematología y Oncología (ACHO). He has been invited to guideline committees, advisory panels, and expert groups advancing standards in multiple myeloma and other hematological malignancies. He has authored 20+ peer-reviewed publications (2023–2025) in journals such as Blood, Blood Advances, Blood Cancer Journal, Clinical Chemistry, Transplantation and Cellular Therapy, and Cancers. His research spans CAR-T outcomes, bispecific antibody efficacy, toxicity prediction, cardiovascular safety, and patient-reported outcomes. Fluent in English, Spanish, and French, Dr. Grajales-Cruz is uniquely positioned for international collaboration, serving as a liaison between North and Latin American oncology communities. As an expert witness, he provides comprehensive case review, oral and written testimony, causation analysis, drug safety evaluation, and malpractice consultation. His blend of clinical authority, academic scholarship, and consulting expertise makes him a trusted figure in hematology-oncology—supporting both patient care and legal stakeholders with evidence-based insight and testimony.